The E7 Oncoprotein Is Translated from Spliced E6*I Transcripts in High-Risk Human Papillomavirus Type 16- or Type 18-Positive Cervical Cancer Cell Lines via Translation Reinitiation
Cell Nucleus
0301 basic medicine
Human papillomavirus 16
Human papillomavirus 18
Transcription, Genetic
RNA Splicing
Retinoblastoma
Down-Regulation
Exons
Oncogene Proteins, Viral
Introns
Cell Line
3. Good health
DNA-Binding Proteins
Repressor Proteins
03 medical and health sciences
Risk Factors
Humans
Female
RNA, Messenger
Phosphorylation
RNA, Small Interfering
Peptide Chain Initiation, Translational
DOI:
10.1128/jvi.80.9.4249-4263.2006
Publication Date:
2006-04-12T19:38:32Z
AUTHORS (4)
ABSTRACT
High-risk human papillomaviruses (HPVs) encode two viral oncoproteins, E6 and E7, from a single bicistronic pre-mRNA containing three exons introns. Retention of intron 1 in the coding region is essential for production full-length oncoprotein. However, splicing extremely efficient cervical cancer cells, leading to spliced transcript, E6*I, E6. Here, we investigated whether this might benefit E7 production. Using RNA interference as tool, targeted using small interfering RNAs (siRNAs) HPV-positive cell lines. At an effective low dose, siRNAs specifically suppressed expression but not expression, demonstrated by stabilization p53. at high doses HPV18 1-specific siRNA substantially reduced level 18E6*I mRNA lacking HeLa implying its nuclear silencing on before splicing. Two other targeting exon 2 regions HPV16 -18, which oncoprotein, E6*I mRNAs remarkable extent preferentially accumulation hypophosphorylated p105Rb cycle arrest, indicating that majority proteins are translational products mRNAs. This was confirmed transient transfection 293 cells: could be translated only open reading frame (ORF) distance-dependent matter upstream ORF translation reinitiation. The data thus provide direct evidence high-risk HPVs responsible
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (42)
CITATIONS (190)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....